AlphaNa Bioscience

AlphaNa Bioscience is a preclinical-stage biotechnology company developing a proprietary platform for next-generation RNA therapeutics. The company’s core technology, Alpha-RNA, utilizes unique structural modifications to create RNA molecules with significantly enhanced stability and protein expression compared to traditional linear mRNA. By optimizing the architectural properties of RNA, AlphaNa aims to overcome current limitations in durability and tissue-specific delivery. The company is primarily focused on applying this platform to treat oncology, rare genetic disorders, and infectious diseases. Headquartered in Cambridge, Massachusetts, AlphaNa is backed by leading venture capital firms and led by experts in RNA biology and drug delivery.